Donna Rowen BA, MSc, PhD (Sheffield)
Tel: 0114 222 0728
I joined HEDS as a health economist in September 2006. Prior to joining HEDS I worked as a teaching assistant in Economics at the University of Sheffield whilst undertaking a PhD in Economics.
My research interests are:
- Measuring and valuing health and quality of life
- Modelling preference data
- Methodology of developing preference-based measures of health from existing measures
- Mapping between measures to generate utility values
- Measuring and valuing child health
My teaching interests lie in health economics, in particular QALYs, utilities and outcome measurement.
I am interested in supervising research students in topics/areas related to measuring and valuing health, in particular deriving, estimating and using utility data for health technology assessment.
I am a member of EEPRU, the Department of Health Policy Research Unit in the Economic Methods of Evaluation of Health and Care Interventions. I am also on the editorial board for Medical Decision Making.
Since joining ScHARR I have worked on a variety of projects including an MRC-NIHR Methodology Programme project on developing and testing methods for deriving condition-specific measures of health from existing condition-specific measures to estimate QALYs. I have also undertaken NICE DSU technical support documents for estimating utilities focussing on mapping and alternative measures to EQ-5D. I have also estimated societal values for burden of illness and end of life as part of EEPRU.
I am currently working on a project to elicit preferences around the aspects of quality of mental healthcare from mental healthcare service users, mental healthcare professionals and members of the general population.
- Rowen D, Carlton J & Elliott J (2019) PROM validation using paper-based or online surveys : data collection methods affect the sociodemographic and health profile of the sample. Value in Health, 22(8), 845-850. View this article in WRRO
- Mukuria C, Rowen D, Harnan S, Rawdin A, Wong R, Ara R & Brazier J (2019) An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values. Applied Health Economics and Health Policy, 17(3), 295-313. View this article in WRRO
- Rowen DL, Mulhern B, Stevens K & Vermaire E (2018) Estimating a Dutch value set for the paediatric preference-based CHU-9D using a discrete choice experiment with duration. Value in Health. View this article in WRRO
- Rowen DL, Azzabi Zouraq I, Chevrou-Severac H & van Hout B (2017) INTERNATIONAL REGULATIONS AND RECOMMENDATIONS FOR UTILITY DATA FOR HEALTH TECHNOLOGY ASSESSMENT. PharmacoEconomics, 35(Suppl 1), 11-19. View this article in WRRO
- Rowen DL, Brazier J, Ara R & Azzabi Zouraq I (2017) The Role Of Condition-Specific Preference-Based Measures In Health Technology Assessment. PharmacoEconomics, 35(Suppl 1), 33-41. View this article in WRRO
- Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S & Shackley P (2016) Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life. Medical Decision Making, 36(2), 210-222.
- Rowen D, Brazier J & Van Hout B (2015) A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
- Longworth L & Rowen D (2013) Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.. Value Health, 16(1), 202-210.
- Brazier JE, Yang Y, Tsuchiya A & Rowen DL (2010) A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.. Eur J Health Econ, 11(2), 215-225.
- Rowen D, Brazier J & Roberts J (2009) Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. Health Qual Life Outcomes, 7, 27.
- Rowen D, Rivero-Arias O, Devlin N & Ratcliffe J () Review of valuation methods of preference-based measures of health for economic evaluation in child and adolescent populations: Where are we now and where are we going?. PharmacoEconomics. View this article in WRRO